Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 9—September 2004


SARS Antibody Test for Serosurveillance

Po-Ren Hsueh*1, Chuan-Liang Kao*1, Cun-Nan Lee*, Li-Kuan Chen†, Mei-Shian Ho‡, Charles Sia§¶, Xin De Fang§, Shugene Lynn¶, Tseng Yuan Chang§, Shi Kau Liu§, Alan M. Walfield§, and Chang Yi Wang§¶Comments to Author 
Author affiliations: *National Taiwan University College of Medicine, Taipei, Taiwan; †Tsu Chi University, Hualien, Taiwan; ‡Academia Sinica, Taipei, Taiwan; §United Biomedical, Inc., Hauppauge, New York, USA; ¶United Biomedical, Inc. Asia, Hsin Chu, Taiwan; 1Drs. Hsueh and Kao contributed equally to this article.

Main Article

Table 1

Sensitivity of peptide-based SARS-CoV ELISA from two patients at NTUa

Patient/day A450nm S/C ratio
SARS patient 1
  Day 0 0.119 0.44
  Day 11 1.638 6.09
  Day 17 2.447 9.10
  Day 38 2.749 10.22
  Day 97 2.600 9.67
SARS patient 2
  Day 0 0.068 0.25
  Day 6 0.163 0.61
  Day 16 0.345 1.28
  Day 27 1.212 4.51
  Day 116 >3.000 >9.40

aSARS, severe acute respiratory syndrome; CoV, coronavirus; ELISA, enzyme-linked immunosorbent assay; S/C = signal/cutoff ratio; NTU, National Taiwan University.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO